Sarcoidosis or sarc is a multisystem disorder characterized by granuloma, ball-like encapsulations of phagocytic cells driven by microbes. Sarcoidosis is often called the “great masquerader” as there may be several atypical or nonspecific presentations – including not just the lungs but the brain, lymph glands, spleen, liver, skin and heart among others.1
An infectious etiology of sarcoidosis has long been suspected. Today scientific evidence provides a strong, if not conclusive, link between infectious agents and sarcoidosis.2
Today scientific evidence provides a strong, if not conclusive, link between infectious agents and sarcoidosis.4
An infectious etiology of sarcoidosis has long been suspected and investigated, sometimes with inconsistent results. For example, the histologic similarity of sarcoidosis to Mycobacterium tuberculosis (see discussion of granuloma below) infection led to the “extensive” evaluation of this organism as a possible etiologic factor.5 The findings have been mixed with some investigators finding evidence of M. tuberculosis6 7 and some failing to confirm this work.8 9 10 11 12 In their 1996 review of mycobacteria's possible role in sarcoidosis, Zumla and James list 15 studies evaluating a mycobacterial cause of sarcoidosis, only three of which were negative.13
There appear to several reasons why researchers have failed to definitively link microbes to sarcoidosis in all cases. For one, even today researchers adhere to the antiquated model of disease set forth by Koch's postulates namely that a pathogen must be: found in all cases of the disease examined, prepared and maintained in a pure culture, capable of producing the original infection, even after several generations in culture, and retrievable from an inoculated animal and cultured again. For all their lingering influence, Koch's postulates never anticipated the era of the human metagenome in which thousands of difficult or impossible-to-culture species of bacteria – rather than just one – contribute to a single disease state. Indeed, the notion of a single causative agent is not in keeping with the worldwide distribution of sarcoidosis.14 Koch's century-old ideas have held science back from understanding how chronic disease occurs because they make no provision for these facts.
The following types and species of bacteria have been found in patients with sarcoidosis, especially the granuloma:
Mycobacterial and propionibacterial DNA have been found in the lymph nodes of Japanese and European patients with sarcoidosis.35
A granuloma is a ball of immune cells associated with various disease states including sarcoidosis, Crohn's, and tuberculosis. (Hence, the term “granulomatous diseases.”) The presence of noncaseating (no tissue death) granuloma of the lungs is the hallmark of sarcoidosis. In sarcoidosis, granuloma are most commonly found in the alveolar septa, the walls of bronchi, and the pulmonary arteries and veins.
At their core, granuloma contain cells from the innate immune system: macrophages and monocytes. Lymphocytes, which are a part of the adaptive or acquired immune system, tend to exist on the periphery or in latter stages of development.36 37
Granulomas may represent an extreme form of innate immune dysfunction.38 The macrophages and monocytes in granuloma are infected by intracellular pathogens such as Mycobacteria. When infected, the internal chemistry of innate immune cells is altered such that these cells no longer undergo apoptosis (programmed cell death).39 Significant differences in the expression of apoptosis-related genes were found in peripheral blood of patients with acute onset sarcoidosis.40
Also, they cease to move towards chemical signals driving an immune response, instead aggregating in clumps. One other side effect of infected macrophages is the dysregulation of the Vitamin D Receptor, leading to the high levels of 1,25-D characteristic of chronic inflammatory diseases.
In a number of diseases such as tuberculosis, leprosy, histoplasmosis, cryptococcosis, blastomycosis, coccidioidomycosis and syphilis, the formation of a granuloma is widely considered to be an indication of infection.41 Even so, many researchers continue to assume that certain chronic diseases such as sarcoidosis and Crohn's disease are not caused by infection even though they present with granuloma which are similar to those found in diseases known to be infectious.
In fact, the presence of granuloma are entirely consistent with an infectious disease. For example, a Japanese team showed that one could use Propionibacterium acnes in mice to induce lung granuloma mimicking sarcoidosis.42 The distinction between infectious and “non-infectious” granulomatous diseases, may be further complicated by reports such as those by Warrier who reported a case of cutaneous sarcoidosis, the histology of which showed tuberculoid granuloma.43
Some researchers have argued that, rather than be a host-protective structures formed to contain infection,44 granuloma may be exploited to expand and disseminate an infection. A Cell paper explains how Mycobacteria implicated in tuberculosis may recruit new macrophages to, nascent granulomas.45
Patients with autoimmune disease often show inconsistent signs of autoimmune reactivity.
Kanchwala et al. showed that patients with sarcoidosis expressed the antimicrobial peptide cathelicidin less than healthy subjects, and that sicker sarcoidosis patients expressed it least of all.61 Wiken et al. showed that there was a reduced TLR2 mRNA expression in patients with Lofgren's syndrome (a type of acute sarcoidosis).62 Note that TLR2 (which the Marshall Pathogenesis theorizes is downregulated in autoimmune disease states) is expressed by the VDR.
No definitive laboratory test diagnostic of sarcoidosis has been identified. For example, sarcoidosis is not diagnosed by the presence of certain antibodies as there usually are none.63
In the absence of a single agreed upon etiologic agent, sarcoidosis often remains a diagnosis of exclusion, although a typical presentation may strongly suggest the diagnosis. The diagnosis of sarcoidosis is established when a compatible clinical and radiographic picture is supported by histologic evidence of noncaseating granulomas in affected tissues and exclusion of other granulomatous diseases (e.g. Crohn's) capable of producing a similar histologic or clinical picture. Note that sarcoidosis is sometimes confused with benign or malignant cancerous tumors.64 Patients should make their doctors aware of any previous sarcoidosis diagnosis (even if only suspected) so sarcoidosis can be investigated as a possible cause of any lumps or tumors.
The MP medication olmesartan blocks formation of fibrotic tissue. However, given that the MP works through generating immunopathology, it would be expected that some sarcoidosis patients on the MP experience a temporary increase in signs of their disease. This would include temporary increases in the appearance of fibrotic tissue and size of lymph nodes a visible on an x-ray. Earlier in the course of therapy, patients are likely to see the most change in the gas transfer coefficient, the DLco, which most doctors don't measure because it can't be done with the simple office spirometer.
Its reputation for spontaneous remission not withstanding, chronic inflammatory diseases such as sarcoidosis never go away on their own. It’s not that patients with sarcoidosis don't experience periods where they might feel better. Unfortunately, these intervals are usually a sign that the immune system has become severely compromised. In sarcoidosis, symptom resolution tends to be temporary as evidence by the epidemiological research.
The Marshall Protocol is a treatment for sarcoidosis. Other treatments (some of which are contraindicated) include the following.
For many physicians, immunosuppressive medications are a first-line treatment for sarcoidosis. These drugs suppress the innate immune response, which provides some patients with temporary symptom palliation, because they reduce immunopathology, the bacterial die-off reaction.
In the face of end-stage pulmonary sarcoidosis, many pulmonologists advise patients to consider lung transplantation. While a number of patients with advanced forms of sarcoidosis (including many who need supplemental oxygen) have done well on the MP, lung transplantation for sarcoidosis is problematic for several reasons.
A lung transplant fails to address the underlying cause, and, as a result, disease reoccurrence is not uncommon. A Danish study showed that lungs implanted in sarcoid patients are reinfected with granulomas five months later (reinfection was determined to come from the recipient patient)71 while another study showed recurrent sarcoidosis occurred as late as 56 months after the procedure.72
According to several observational studies, the median survival time of sarcoidosis patients after they receive a transplant has been reported to be about 4.7 years73 – about half that of other major transplanted organ recipients.
Finally, any quality of life during time following transplant is limit. To ward off tissue rejection and survive several years, patients must take a cocktail of anti-rejection and immunosuppressive drugs, classes of drugs which entale a number of side effects.
There are at least several patients who have chosen to do MP rather than be on a Transplant List.
Under most normal conditions, serum levels of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25-D), are constant throughout the year (no variability due to sun exposure),74 but there is no such tight biochemical regulation in at least some chronic inflammatory diseases such as sarcoidosis. Patients with sarcoidosis tend to have high levels of 1,25-D. As the article Metabolism of vitamin D and the Vitamin D Receptor explains, these high levels may be a direct outcome of microbes' effect on slowing activity of the VDR. It is also an indication of innate immune dysfunction.
It is sometimes thought that the liver and kidney are the only sites for conversion of 25-D into 1,25-D, but this process happens outside those organs – not coincidentally, at the very sites where patients report symptoms of chronic disease. High levels of 1,25-D and the enzyme which leads to the production of 1,25-D, 1 α-hydroxylase, have been found at various locations where the human body needs a strong host defense.75 Zehnder et al found increased expression of the enzyme 1 α-hydroxylase – the enzyme which converts 25-D into 1,25-D – in the skin cells of sarcoidosis patients where sarcoidosis patients tend to have disease symptoms.76 They write:
In particular, the expression of 1α-OHase [1 α-hydroxylase] by activated macrophages and epidermal keratinocytes [skin cells] suggests a role for 1,25(OH)2D3 [1,25-D] as an immunomodulatory and/or antiproliferative hormone.
A number of studies have demonstrated that the level of the hormone 1,25-D rises in patients with certain chronic diseases. Kavathia et al. found that in patients with sarcoidosis, those with high serum levels of 1,25-D have more pronounced chronic treatment needs.77
Hypercalcemia (excess levels of calcium in the blood) and hypercalciuria (excessive urinary calcium excretion) are frequently associated with the granulomatous diseases. Prevalence data suggests that 30 to 50 percent of patients with sarcoidosis have hypercalciuria and 10 to 20 percent have hypercalcemia.78 79 Until recently, some researchers suggested that these processes were caused by high levels of 1,25-D.80 81 As a result, patients with granulomatous disease are widely cautioned to limit sunlight exposure and vitamin D ingestion – recommendations that are generally not offered to patients with other chronic inflammatory diseases. Even pro-vitamin D advocates such as Michael Holick, M.D. have issued such cautions for high-dose supplementation of vitamin D in granulomatous diseases.82
However, according to the Marshall Pathogenesis, any essential discrepancy in calcium/VDR metabolism between the granulomatous and non-granulomatous diseases is limited. The prevalence data suggests as much. Not everyone who has sarcoidosis gets hypercalcemia, and a large number of patients with other diseases such as breast and lung cancers are at risk for the condition.83 Further, in many diseases for which hypercalcemia is not suspected, the condition tends to go underdiagnosed.
Consistent with its classically understood role in maintaining bone health, the Vitamin D Receptor does appear to play at least some direct role in calcium regulation: a 2010 paper showed that the VDR signals stem cells responsible for osteoblast (bone-building) activity.84 But, researchers have since emphasized the role of estrogens and the estrogen receptor in maintaining bone health.85 In a 2007 study in Cell, Nakamura and colleagues showed that, in a female mouse model, removing estrogen receptor alpha in osteoblasts demonstrated that estrogen directly induces osteoclast apoptosis.86 The loss of estrogen among women at menopause may play some role in this process, but it is too soon to say this relationship is causal. Nakamura's work was done in otherwise healthy mouse cells rather than in human cells – which may be infected by pathogens. If such cells were infected, supplementation with estrogen would not address the underlying disease process.
An analysis of the 2001 ACCESS study challenged the widely held stereotype that the American patients most often affected by sarcoidosis are African-Americans and under 40.87
Sarcoidosis can affect any organ, initially presenting with one or more of the following abnormalities (in order of frequency according to the 2001 ACCESS study, which used data collected by pulmonologists).88
A variety of strategies that do not involve medication are available for patients who have uncomfortable respiratory symptoms including breathing exercises, getting more fluids, rest, and others. Also, patients have reported relief taking guaifenesin, using bronchodilator inhalers (steroid inhalers are contraindicated), and nebulizers. Supplemental oxygen may be useful or necessary in some cases even though it may be needed only for a few hours a day for a few months.
While it is certainly possible to contract an acute respiratory infection while on the Marshall Protocol, many symptoms of immunopathology mimic those of an acute respiratory infection. Early recognition and effective management of immunopathology are very important when a patient has respiratory symptoms. Any symptom that correlates with MP therapy may be due to immunopathology.
Emergency medical personnel should know that a patient is on the MP. The article Notice for health care providers provides information that emergency medical personnel need to know.
A cough can develop at any time in sarcoidosis. It can be related to anything from upper respiratory involvement and post-nasal drip to chest involvement or even triggered by exposure to dust, fungus, odors or fumes.
Cutaneous manifestations of sarcoidosis are common and varied, and one patient can have different types of sarcoid skin lesions at the same time. Because of its diverse skin manifestations, sarcoidosis is most frequently diagnosed by a dermatologist. When a patient with sarcoidosis presents with skin problems, physicians should be alert to sarcoidosis as likely the source of these problems.
Lupus pernio is not another disease, nor is it related to lupus. Lupus pernio is a chronic plaquelike hardening of the face, usually appearing with violet discoloration of the cheeks, lips, nose, and ears. It can erode into cartilage or bone. Lupus pernio lesions can be permanently disfiguring and cause a patient to feel embarrassed, particularly since they may be noticeable on facial areas so visible to the public.
Sometimes lupus pernio lesions will have an appearance of small “beads” along their edge, especially if the sore is on the rim of the nose. Like some other cutaneous sarcoidosis lesions, lupus pernio can appear at sites of old scars or trauma94 as well as in the upper respiratory tract95 – both sites of which can be quite resistant to the standard immunosuppressive therapies. These lesions can occur when the nose, face or hands are exposed to cold or wind, so it's a good idea for patients with sacroidosis to keep these areas protected from wind and cold. Avoiding exposure to bright lights is also an important preventative measure. Lupus pernio is said to be the skin lesion most characteristic (a diagnostic indicator) of sarcoidosis96, but not all sarcoidosis patients have these skin lesions.
Erythema nodosum are raised red, tender nodular lesions, generally but not exclusively on the anterior surface of the lower part of the leg. These lesions do not represent granulomatous involvement of the skin. Rather, the histopathology is primarily that of a panniculitis (inflammation of the fatty layer under the skin), with cellular inflammation and edema of the deep dermis and subcutaneous tissue. The presence of erythema nodosum is commonly observed in other infectious diseases such as tuberculosis.97
The reported frequency of ocular manifestations for sarcoidosis varies according to the source and group studied, but may be as high as 70%.98 In the eye, the common sites of involvement are the skin of eyelid, conjunctiva, uveal tract, retina, optic nerve and lacrimal gland.99 Common symptoms of ocular sarcoidosis include:
Some asymptomatic patients still have active inflammation. Initially asymptomatic patients with ocular sarcoidosis can eventually develop blindness. Therefore, it is recommended that all patients with sarcoidosis receive a dedicated ophthalmologic examination.
Columbia University researcher Emil Wirotsko identified cell wall deficient bacteria – which he described as “mollicute-like organisms” – in the vitreous fluid of sarcoidal eyes.101 He further showed that the introduction of these microbes into mouse model effectively reproduced the chronic inflammatory process and granuloma that are the hallmark of sarcoidosis.
A lymph node, also called a gland, is a small ball-shaped organ of the immune system, distributed widely throughout the body and linked by lymphatic vessels. Lymph nodes are garrisons of B, T, and other immune cells. Lymph nodes are found all through the body, and act as filters or traps for foreign particles.
Lymph nodes play a vital role in the body's ability to fight off microbes. During an infection, the lymph nodes can expand due to intense B-cell proliferation in the germinal centers, a condition commonly referred to as “swollen glands.” Lymphadenopathy refers to “disease of the lymph nodes.” It is, however, almost synonymously used with “swollen or enlarged lymph nodes.” Lymphadenopathy can occur anywhere there are lymph node, but especially the neck, armpits, groin, or chest. Enlarged or tender glands can often be detected by low-tech means: visually or by palpation. Lymph nodes deep in the groin or beneath the ribs in the chest can be monitored with imaging such as chest x-ray, CT or PET scan.
Like any sarcoidosis symptom, lymphadenopathy may flare with immunopathology, resulting in enlarged and/or tender lymph nodes. The increase in the size of lymph nodes is consistent with an immunostimulatory therapy such as the Marshall Protocol. However, in later stages of sarcoidosis the lymph nodes shrink as their functionality decreases. This may be because they become too damaged to function. It is not unusual for lymph nodes to be calcified in sarcoidosis patients.102
While it is true that chest pain can be due to cardiac involvement, it may simply be due to other problems brought on by sarcoidosis such as enlarged lymph nodes which can cause pressure, crowding and pain in the chest. Enlarged lymph noses can also result in bronchial obstructions.
Massage can increase lymphatic flow103 as can osteopathic manipulation.104 Patients seeking this kind of therapy should look for therapists competent in techniques to help the lymphatic system and familiar with the needs of patients with chronic illness.
Sarcoidosis of the liver is not uncommon.105 According to Richard W Goodgame, MD, “The prevalence of hepatic granulomas in sarcoidosis is 65%. In a study of 100 patients with hepatic sarcoidosis, the majority of patients were asymptomatic and had normal abdominal examinations.”
The angtiotensin receptor blocker olmesartan has been shown to reduce liver fibrosis106 and aid liver healing.107 Some patients with sarcoidosis of the liver are mistakenly told they have “fatty liver disease” or cirrhosis.
The reported frequency of splenomegaly, enlargement or inflammation of the spleen, in sarcoidosis has ranged from 1% to 40%.108
Neurosarcoidosis (sometimes shortened to neurosarcoid) refers to sarcoidosis involving the central nervous system (brain and spinal cord). It can have many manifestations, but abnormalities of the cranial nerves (a group of twelve nerves supplying the head and neck area) are the most common. It may develop acutely, subacutely, and chronically. Approximately 5-10% of people with sarcoidosis of other organs develop central nervous system involvement. Only 1% of people with sarcoidosis will have neurosarcoidosis alone without involvement of any other organs. Diagnosis can be difficult, with no test apart from biopsy being completely reliable.
Psychiatric problems occur in 20% of cases; many different disorders have been reported, e.g. depression and psychosis. Peripheral neuropathy has been reported in up to 15% of cases of neurosarcoidosis.109
According to a 2003 study of Dutch patients, 30% of people with sarcoidosis suffer from chest pain.110 A similar proportion of sarcoidosis patients were found to have cardiac involvement upon autopsy.111 A third paper found that perhaps 50% of sarcoidosis patients have cardiac involvement that is not diagnosed112.
While it is true that chest pain can be due to cardiac involvement,113 it may simply be due to other problems brought on by sarcoidosis such as enlarged lymph nodes which can cause pressure, crowding and pain in the chest.
All sarcoidosis patients are cautioned to assume they may have unrecognized cardiac involvement and to control their level of immunopathology accordingly.
While a severe cardiac immunopathological reaction is rare, it has the potential to be life-threatening. Therefore, health care providers are cautioned to be on the alert for cardiac symptoms in all their patients. Also, patients with risk factors or legitimate cause for concern should know when seek medical attention.
sarcoidosis, bladder cancer
Read the interview
Read the interview
sarcoidosis, rheumatoid arthritis
Read the interview
sarcoidosis (Heerfordt's Syndrome), uveitis
Read the interview
Read the interview
neurosarcoidosis, systemic sarcoidosis; spasticity, myasthenia, CNS dysfunction, joint pain, pulmonary, splenic and cardiac involvement
Read the interview
Interviews of patients with other diseases are also available.
I just returned from a wonderful family vacation in Disney World. I was so excited that I was able to walk and keep up with my family… mostly, anyway and didn't need a wheelchair! When we booked our trip 10 months ago, I was planning to reserve a wheelchair to access the monorail and keep up with my family. As the summer progressed and I was feeling better I was confident that I was able to walk up ramps, etc. and did! The other wonderful news I have is that I was able to fly round trip from Alaska to Florida keeping my oxygen saturation above 90% without supplemental oxygen! I had my approved POC with Doctor's prescription etc. if needed, but my saturation was good as was my heart rate between 55 bpm and 75 bpm! I am thrilled!
Sue Lyons, MarshallProtocol.com
It's been a long time since I posted and am ashamed of being so remiss. I do not go on the computer very often but I do read everyone's post especially if it has information that I want to know.
I have been on the MP for almost five years now and have seen a lot of improvement although I still have a good way to go. I am down to taking only benicar 40mg every six hours and feel that it is helping me a lot. Before MP I was on a lot of medications but most of the symptoms have been resolved.
My cholesterol has dropped to a reasonable level, blood pressure has dropped, bone density has improved. Before MP I was on so many medications for high blood pressure, osteoporosis, high cholesterol. I still have occasional dizziness and my hearing has become very poor, I cannot walk without a walker. I had another MRI in November last year and my doctor said that the tumor in my brain is still very small but it is benign and it is really of no significance so I was pleased about that.
I went in March and had a screening test and all the tests came back normal which is very encouraging.
I will try and post regularly as I have a little more time on my hands now.
I am doing well. I completed phase three and right now I am on Benicar every six hours and max dose of zith every eight days as per Dr. Bleny's instruction. As I posted earlier, in January this year I had a chest x-ray which showed improvement. My sun tolerance has improved and my energy as well. My major problem at the moment is my knee. I think this will also go away with time.
Some of my blood markers are off:
- Potassium 5.5 - range 3.3 - 5.1 mmol/L
- Triglycerides - 2.9 - range <2.30 mmol/L
I am currently taking Soda Bicarb tablets every day.
smoking reduces risk
Am J Respir Crit Care Med. 2004 Apr 15;169(8):893-5.
Is smoking beneficial for granulomatous lung diseases?
Maier LA. Comment in: Am J Respir Crit Care Med. 2004 Jul 15;170(2):199-200; author reply 200. Am J Respir Crit Care Med. 2004 Oct 1;170(7):821; author reply 821. Comment on: Am J Respir Crit Care Med. 2004 Apr 15;169(8):903-9.
The Etiologic Agent of SarcoidosisWhat If There Isn’t One?